Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

In this article

U.S. drugmaker Eli Lilly

is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, The Wall Street Journal reported on Sunday.

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones, the Journal added, citing people.

Reuters could not immediately verify the report. Eli Lilly and Kelonia Therapeutics did not immediately respond to Reuters’ request for comment outside regular business hours.

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Related reading

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7…

Eli Lilly looks beyond its blockbuster obesity drugs with another smart deal

Celltrion vows to invest $1 billion to buy, upgrade U.S. Lilly plant - UPI.com

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs…

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental…

Leerink upgrades Eli Lilly following landmark deal with U.S. government